## **PATENT**

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)

Suthanthiran, et al.

Examiner:

Gary B. Nickol

Serial No.:

10/627,408

Group Art Unit:

1642

Confirmation No:

2823

Docket:

955-10 P/CON/DIV

Filed:

July 25, 2003

Dated:

February 21, 2006

For:

USE OF ANTIOTENSIN II INHIBITORS TO PREVENT

MALIGNANCIES ASSOCIATED WITH IMMUNOSUPPRESSION

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 I hereby certify this correspondence is being deposited with the United States Postal Service as first class mail, postpaid in an envelope, addressed to:

Commissioner for Patents, P.O. Box 1450,

Alexandria, Virginia 22313-1450

on <u>February 21, 2006</u>

## RESPONSE TO RESTRICTION REQUIREMENT

Sir:

In an Office Action mailed November 22, 2005, the Examiner has imposed a Restriction Requirement to one of the following inventions under the provisions of 35 U.S.C. §121:

Group I. Claims 1-2, 4, 14, drawn to a method for reducing or preventing formation or metastasis of a neoplasm in a mammal comprising treating the mammal with an effective amount of an angiotensin II inhibitor wherein the inhibitor is an angiotensin converting enzyme (ACE) inhibitor, classified in class 424,

subclass 184.1; class 514, subclass 1.

Suthanthiran et al. Serial No. 10/627,408 Filed: July 25, 2003 Page 2 of 3

- Group II. Claims 1-3, 5, 12, 14 drawin to a method for reducing or preventing formation or metastasis of a neoplasm in a mammal comprising treating the mammal with an effective amount of an angiotensin II inhibitor wherein the inhibitor comprises an anti-angiotensin II antibody, classified in class 424, subclass 130.1.
- Group III. Claims 1-2, 6, 14, drawn to a method for reducing or preventing formation or metastasis of a neoplasm in a mammal comprising treating the mammal with an effective amount of an angiotension II inhibitor wherein the inhibitor comprises an *anti-angiotension I antibody*, classified in class 424, subclass 130.1.
- Group IV. Claims 1-2, 7, 14, drawn to a method for reducing or preventing formation or metastasis of a neoplasm in a mammal comprising treating the mammal with an effective amount of an angiotensin II inhibitor wherein the inhibitor comprises an *anti-angiotensinogen antibody*, classified in class 424, subclass 130.1.
- Group V. Claims 1-3, 8, 14, drawn to a method for reducing or preventing formation or metastasis of a neoplasm in a mammal comprising treating the mammal with an effective amount of an angiotensin II inhibitor wherein the inhibitor is a protein or peptide, classified in class 424, subclass 184.1.
- Group VI. Claims 1-2, 9-10, 14, drawn to a method for reducing or preventing formation or metastasis of a neoplasm in a mammal comprising treating the mammal with an effective amount of an angiotensin II inhibitor wherein the angiotensin II inhibitor is a renin inhibitor, classified in class 530, subclass 860.
- Group VII. Claims 1-2, 11, 14, drawn to a method for reducing or preventing formation or metastasis of a neoplasm in a mammal comprising treating the mammal with an effective amount of an angiotensin II inhibitor wherein the inhibitor blocks expression of angiotensinogen, classified in class 514, subclass 44.
- Group VIII. Claims 1-2, 13-14, drawn to a method for reducing or preventing formation or metastasis of a neoplasm in a mammal comprising treating the mammal with an effective amount of an angiotensin II inhibitor wherein the inhibitor is a small molecule, classified in class 514, subclass 1.

In response to the Restriction Requirement, Applicants elect the subject matter defined by the claims of Group VIII (claims 1-2 and 13-14), without traverse.

Suthanthiran et al. Serial No. 10/627,408 Filed: July 25, 2003

Page 3 of 3

8

Applicants reserve the right to pursue the claims of the non-elected Groups in

divisional applications.

It is now believed that this application is in condition for further consideration and

examination. If resolution of any remaining issues are required prior to examination of the

application, it is respectfully requested that the Examiner contact Applicants' agent at the

telephone number provided below.

Respectfully submitted,

Edna I. Gergel, Ph.D.

Registration No.: 50,819 Agent for Applicant(s)

HOFFMANN & BARON, LLP 6900 Jericho Turnpike Syosset, New York 11791 (516) 822-3550 EIG:sbs

217452\_1

3